Two years after being diagnosed with multiple myeloma and treated with the Dara-Rd regimen as induction therapy, a 78-year-old patient presented with mild fatigue during routine follow-up. James E. Hoffman, MD, discussed the case with a group of peers.
Research in the solid tumors arena around the combination of the oncolytic virus technology CF33-CD19 and the CD19-targeting CAR placental-derived T-cell therapy CyCART-19, is underway to explore it’s potential in this patient population.
Following the success of a phase 1 study that showed its potential for accelerated FDA approval in the future, the WEE-1 inhibitor, ZN-c3 has been dosed for the first time in the newly launched phase 2 study, which is exploring the agent for the treatment of adult women with recurrent or persistent uterine serous carcinoma.
The combination of plinabulin with docetaxel showed improvement in overall survival compared with docetaxel alone as treatment of patients with second- and third-line non –small cell lung cancer with EGFR wild type, meeting the primary end point of the phase 3 DUBLIN-3 clinical trial.
In an interview with Targeted Oncology™, Kamran A. Ahmed, MD, discussed the novel treatment strategy of combining radiotherapy with intrathecal trastuzumab/pertuzumab as well as and the rationale behind the combination.
In an interview with Targeted Oncology™, Rhonda L. Bitting, MD, discussed the efficacy results and key takeaways of a study investigating low-dose paclitaxel plus pembrolizumab in patients with platinum-refractory UC.
Bristol Myers Squibb has decided to withdraw the approval for romidepsin, a histone deacetylase inhibitor, for the treatment of adults with peripheral T-cell lymphoma who received at least 1 prior therapy after a confirmatory phase 3 study missed its primary end point.